Introduction
Prostate cancer is the most frequently diagnosed cancer and the second most common cause of cancer death in men in North America (Parker et al. 1996) .
In fact, it is predicted by the American Cancer Society that 317 100 new cases of prostate cancer will be diagnosed in the United States in 1996 while 41 400 men will die from the disease during the same period. In the absence of a significant improvement in the prevention and/or treatment of this cancer, its major medicosocial and economic impact will continue to rise, especially as the population ages.
The best known characteristic of prostate cancer is its high sensitivity to androgen deprivation. In fact, among all hormone-sensitive cancers, prostate cancer is, by far, the one showing the best response to endocrine therapy (Labrie 1995 , Labrie et al. 1995 . For more than 50 years, following the pioneering report of Huggins & Hodges (1941) (Labrie etal. 1980 (Labrie etal. ,1986 causes a 90-95% reduction in serum testosterone and dihydrotestosterone (DHT) concentration, a much smaller inhibitory effect is seen on the intraprostatic concentration of DHT. In fact, after elimination of testicular andro¬ gens by medical or surgical castration, the intraprostatic concentration of the active androgen DHT remains at 40-50% of the value measured in the prostates of intact control men (Labrie et al. 1985 (Labrie et al. , 1994 , thus leaving an important amount of andro¬ gens free to continue to stimulate prostate cancer growth after castration.
Contrary to the misconception that the testes are responsible for 90-95% of total androgen production in men as suggested by simple measurement of serum testosterone (Gittes 1991) , it is now well demonstrated that prostatic cells efficiently trans¬ form the inactive steroid precursors of adrenal origin, namely dehydroepiandrosterone sulfate and dehydroepiandrosterone, into the active androgens testosterone and DHT. In fact, as mentioned above, the amounts of testosterone and DHT synthesized locally in the prostate from adrenal steroid precursors are comparable with the quantity of testosterone and DHT of testicular origin (Labrie 1991 , Labrie et al. 1994 ).
While testicular androgens can be easily and completely eliminated by orchiectomy (Huggins & Hodges 1941) or medical castration with an LHRH agonist (Labrie et al. 1980 (Labrie et al. , 1986 , antiandrogens or compounds that block the interaction of testosterone and DHT with the androgen receptor are the best available means of interfering with the action of the androgens made locally in the prostate (Labrie 1991 (Labrie , 1993 ). The best antiandrogen should be a compound which possesses high specificity and affinity for the androgen receptor while not having any androgenic, estrogenic, progestational, glucocorticoid or any other hormonal or antihormonal activity (Dorfman 1971 , Labrie 1993 While the non-steroidal pure antiandrogens of the class of Flutamide are well recognized to be clearly superior to steroidal antiandrogens (Neri et al. 1967 , 1972 (Labrie et al. 1988è ) was used at passage 19. Cells were routinely grown as previously described (Labrie & Veilleux 1988 In the second experiment, intact rats weighing 215-250 g were randomly divided into the following ten groups, each containing eight animals: (1) Hormone measurements Serum testosterone and DHT were measured by RIA after diethyl ether extraction and chromatography on LH-20 columns using antisera developed and charac¬ terized in our laboratory (Bélanger etal. 1980 (Bélanger etal. ,1989 (Rodbard 1974 (Labrie & Veilleux 1986 Luthy etal. 1988 , Plante etal. 1988 (Labrie & Veilleux 1986 (Fig. 4) . P<0.01) above control at the twice-daily doses of 0.25, 1.0, 4.0, and 16 mg Flutamide/kg body weight, while the same doses of Casodex increased serum LH to 0.39±0.10 ng/ml (95%, N.S.), 0.62+0.11 ng/ ml (210%, N.S.), 0.65±0.15 ng/ml (225%, N.S.), and 1.00±0.29 ng/ml (400%, P<0.01) (Fig. 7) . hand, in the intact rat, Casodex has a lower stimu¬ latory effect on circulating androgen levels. Nilutamide (Anandron), the first derivative of Flutamide to be used clinically (Labrie et al. 1982 (Labrie et al. , 1983 , also produces an important elevation of serum testo¬ sterone levels in intact rats (Moguilewsky et al. 1987 ). Casodex, at the dose of 40 mg/kg has been found to slightly increase serum LH and testosterone concentrations (Chandolia et al. 1991) . In another study performed in intact male rats, Casodex and Flutamide increased serum testosterone levels by two-to threefold and seven-to elevenfold respec¬ tively (Snyder et al. 1989) . In all studies performed in the intact rat, however, Flutamide led to higher levels of serum androgens. In immature castrated male rats, Flutamide, hydroxyFlutamide and Casodex were found to inhibit testosterone propionate-induced ventral prostate weight with comparable potency while being three-to fourfold more potent than cyproterone acetate, a progestational compound (Snyder et al. 1989 (Furr & Milsted 1988 , Lacoste etal. 1988 69-76. 
